Condition category
Infections and Infestations
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Within the UK, completion rates for latent tuberculosis infection (LTBI) treatment regimens are known to be poor. A recent paper described a novel LTBI treatment regimen of Rifapentine/Isoniazid with high completion rates. The aim of this study is to compare completion rates between this novel regimen and a Rifinah regimen and provide useful data to inform future practice. The value for money of this approach is assessed.

Who can participate?
Male or non-pregnant, non-nursing, females, aged between 16 and 65, who test positive for LTBI but do not have active tuberculosis disease

What does the study involve?
Participants are randomly allocated to either twice daily Rifinah or weekly Rifapentine and Isoniazid for 3 months. Treatment adherence and adverse reactions are monitored every month through clinic appointments and for 1 month after treatment completion.

What are the possible benefits and risks of participating?
Participants could reduce their risk of developing active tuberculosis by being treated. Possible side effects include hepatoxicity (damage of the liver). These would be monitored during the study and the treatment would be stopped if clinically indicated.

Where is the study run from?
University College London (UK)

When is the study starting and how long is it expected to run for?
May 2014 to May 2015

Who is funding the study?
Department of Health (UK)

Who is the main contact?
Prof. Ibrahim Abubakar

Trial website

Contact information



Primary contact

Prof Ibrahim Abubakar


Contact details

University College London
Research Department of Infection and Population Health
4th floor Mortimer Market
off Capper Street
United Kingdom
+44 (0)20 7679 0954

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

The HALT LTBI study: Phase IV multi-site, unblinded, randomised trial of prophylactic Rifapentine/Isoniazid versus Rifampicin/Isoniazid (Rifinah) for latent tuberculosis infection (LTBI)


Study hypothesis

Completion rates for individuals treated with Rifapentine/Isoniazid will be higher than for those treated with Rifinah.

Ethics approval

NRES Committee London, Brent, 29/11/2013, ref: 13/LO/1666

Study design

Pilot of a randomised controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting

GP practices

Trial type


Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet


Latent tuberculosis infection


Random allocation to either Rifinah (300mg Rifampicin plus 150mg Isoniazid, two daily) or Rifapentine and Isoniazid (3 months, 12 weekly doses); monthly follow-up for the duration of treatment and one month after treatment completion.

Intervention type



Phase IV

Drug names

Rifampicin, isoniazid, rifapentine

Primary outcome measures

1. Completion of treatment regimen
2. Associated health economics to determine cost effectiveness of the intervention

Secondary outcome measures

Adverse effects of treatment for LTBI

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Male or non-pregnant, non-nursing, female adults aged between 16 years 0 days and 64 years 364 days at enrolment
2. Individuals at high risk for developing tuberculosis but without evidence of active tuberculosis. High-risk is defined on the basis of a positive Interferon Gamma Release Assay (IGRA)
3. People with no evidence of active tuberculosis who have a positive IGRA as defined above
4. Willing and able to provide written informed consent

Participant type


Age group




Target number of participants


Participant exclusion criteria

Current exclusion criteria as of 31/03/2014:
1. Patients unable to give consent
2. Pregnant or breastfeeding women
3. Patients whose weight is under 45 kg
4. Allergies to any of the study drugs or excipients contained in preparations of these medicines
5. Patients requiring medications that cannot be safely taken with the study drugs (see Appendix 2)
6. Any medical condition deserving priority of treatment (such as: porphyria, malabsorption syndromes, Clostridium difficile-associated diarrhoea and other conditions)
7. HIV infection
8. Individuals with known liver disease, defined as LFT (ALT/AST/bilirubin) over upper limit of normal (ULN) at baseline (one abnormal value prevents the patient from participating in the study)
9. Clinical diagnosis of cirrhosis (jaundice, hematemesis, ascites or previous episodes of liver encephalopathy)
10. Chronic/active hepatitis B or hepatitis C virus infection
11. High-risk drinking, according to the Department of Health criteria (regularly drinking more than 8 units a day or 50 units a week for men; regularly drinking more than 6 units a day or 35 units a week for women)
12. Previous treatment for TB or LTBI
13. Individuals who would usually be offered LTBI treatment under Directly Observed Therapy (DOT) because of their mental or social disabilities
14. Use of another experimental investigational medicinal product that is likely to interfere with the study medication within 3 months of study enrolment

Previous exclusion criteria:
1. Females of childbearing potential must be willing to use an effective method of contraception
2. Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for trial treatment
3. Females must not be breastfeeding
4. Allergies to Rifapentine, Isoniazid, Rifampicin or excipients contained in the preparations of these medicines
5. Patients requiring medications that cannot be safely taken with the study drugs
6. High risk drinking, according to the Department of Health criteria
7. Those who are HIV positive
8. Individuals who already have significant liver disease
9. Those who would not be eligible for LTBI treatment under the American Thoracic Society Criteria
10. Individuals who would usually be offered LTBI treatment under Directly Observed Therapy (DOT)

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

University College London
United Kingdom

Trial participating centre

Barts Health, Newham University Hospital
E13 8SL
United Kingdom

Trial participating centre

The Royal Free London NHS Foundation Trust
United Kingdom

Sponsor information


University College London (UK)

Sponsor details

c/o Anne Marie Downey
Joint Research Office
1st Floor Maple House (Suite A)
149 Tottenham Court Road
United Kingdom

Sponsor type




Funder type


Funder name

Department of Health Policy Research Programme (UK) ref: 015/0306

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer reviewed journal within one year of end of study (by 30/06/2018).

IPD sharing statement
The data sharing plans for the current study are unknown and will be made available at a later date.

Intention to publish date


Participant level data

To be made available at a later date

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

23/10/2017: The following changes were made to the trial record: 1. The overall trial end date was changed from 31/05/2015 to 30/06/2017. 2. Publication and dissemination plan and IPD sharing statement added. 31/03/2014: The following changes were made to the trial record: 1. The overall trial start date was changed from 01/04/2013 to 01/05/2014. 2. The overall trial end date was changed from 30/09/2015 to 31/05/2015.